Drugs / Rellidep
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT00446719 | Aug 2007 → Dec 2008 | depressive disorder | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rellidep | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00446719 ↗ |
| Route | Oral | “2000 mg P.O. daily for 8 weeks” NCT00446719 ↗ |